Navigation Links
Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
Date:3/18/2008

BALTIMORE, March 18 /PRNewswire/ -- Alba Therapeutics Corporation today announced that Blake M. Paterson M.D., its CEO and Co-founder, has received the 2008 Leadership in Bioscience Award from the Greater Baltimore Council. Dr. Paterson was recognized from a field of distinguished nominees submitted by businesses, bioscience advocates, higher education institutions and government officials. This is the second successive time that Dr. Paterson has received this award from the Greater Baltimore Council.

Dr. Paterson's leadership accomplishments were examined for evidence of outstanding management practices that led to significant improvement in the company's performance, vision and steps taken to move toward fulfillment of that vision, fostering pioneering work with new or important applications in bioscience, and fundraising achievements. The award was presented today at a breakfast reception hosted by the Greater Baltimore Committee, the region's most prominent organization of business and civic leaders, to recognize outstanding achievements in the region's bioscience industry.

"It is a great honor to receive this award, and it is gratifying to be honored within the Baltimore bioscience and business community," stated Dr. Paterson. "Our goal at Alba has been to work with the 3 P's which include place, people, and perseverance. We are proud to be in the place of Baltimore, our people are working hard to create a new medicine for the unmet medical needs of patients with celiac disease and other inflammatory conditions, and our perseverance and determination toward achieving this goal is what drives us each day. This award recognizes the progress that Alba has made in the past year, and this provides further encouragement in our efforts to address the needs of patients and physicians, to provide value to our investors, and to increase the profile of the Baltimore bioscience community within the region and nationally."

Dr. Paterson has directed the growth of Alba Therapeutics since its inception in 2004, and his leadership has been characterized by methodical and rapid growth. Alba has grown into a thriving Baltimore biotechnology company with 45 employees in its headquarters at the University of Maryland BioPark, and this growth has been punctuated by a series of significant milestones including securing significant venture financing, rapid progress of Alba's clinical candidate (larazotide acetate) into Phase 2b clinical trials, and closure of a licensing and collaboration agreement worth up to $325 million with Shire Pharmaceuticals.

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Alba's technology platform is based upon a key pathway that regulates the assembly and disassembly of tight junctions in cell barriers throughout the body. As a result of its unique technology platform, Alba is a leader in mucosal biology and has developed a pipeline of innovative therapeutic candidates that has the potential to modify the course of disease and significantly improve upon existing treatments for a wide range of diseases such as celiac disease, Crohn's disease, and Asthma/COPD or acute lung injury.

Contact: Bernard McDonald, PhD

Phone: 410-319-0780

E-mail: info@albatherapeutics.com

Web site: http://www.albatherapeutics.com


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
2. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
5. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
6. Nile Therapeutics, Inc. Adds to Executive Management Team
7. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
8. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
9. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
10. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
11. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... City, Missouri (PRWEB) , ... May 27, 2016 , ... ... Development Manager, Turf and Ornamental Products. , In his 15-year career with PBI-Gordon, Dave ... Herbicide Product Manager, where he was integral in the development and launch of many ...
(Date:5/27/2016)... NEW YORK , May 27, 2016 ... state, but investors playing in this space know that volatility ... this morning,s featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: ... CTIC ), Lpath Inc. (NASDAQ: LPTN ), and ... now and gain access to the technical alerts for these ...
(Date:5/26/2016)... , May 26, 2016 Q BioMed ... it will be a featured presenter at the 5th Annual ... New York City at the Grand Hyatt ... , Q BioMed Inc. CEO, is scheduled to begin at ... the company,s business strategy, recent developments and outline milestones for ...
(Date:5/26/2016)... ... 26, 2016 , ... Kinder Scientific (KinderScientific.com), a leading animal ... the Company for the future. Kinder Scientific announces restructured ownership and additional ... appointed Chairman of the Board, Curtis D. Kinghorn has been appointed CEO/President and ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):